Targeting the Epigenome in Hematopoietic Malignancies

E.      Jost; R.      Osieka; O.      Galm

Abstract

Two epigenetic events that are associated with transcriptional silencing in carcinogenesis include hypermethylation of CpG islands near gene promoter regions and changes in chromatin conformation involving histone acetylation. Pharmacologic targeting of these epigenetic processes and upregulation of genes involving fundamental cellular pathways have become a new therapeutic strategy in the treatment of hematopoietic malignancies.

Keywords: Epigenetics, DNA methylation, histone modifications, transcriptional silencing, tumor suppressor genes

« Previous Next »

Rights & Permissions Print Cite

Letters in Drug Design & Discovery

Title: Targeting the Epigenome in Hematopoietic Malignancies

Volume: 3 Issue: 4

Author(s): E. Jost, R. Osieka and O. Galm

Affiliation:

Keywords: Epigenetics, DNA methylation, histone modifications, transcriptional silencing, tumor suppressor genes

Abstract: Two epigenetic events that are associated with transcriptional silencing in carcinogenesis include hypermethylation of CpG islands near gene promoter regions and changes in chromatin conformation involving histone acetylation. Pharmacologic targeting of these epigenetic processes and upregulation of genes involving fundamental cellular pathways have become a new therapeutic strategy in the treatment of hematopoietic malignancies.

Export Options

Export File:

RIS (for EndNote, Reference Manager, ProCite)

BibTeX

Text

Content:

Citation Only

Citation and Abstract

About this article

Cite this article as:

Jost E., Osieka R. and Galm O., Targeting the Epigenome in Hematopoietic Malignancies, Letters in Drug Design & Discovery 2006; 3 (4) . https://dx.doi.org/10.2174/157018006776743251